On August 31, CANSINOBIO fell 5.48% in regular trading, trading at HK$29.54/share, with turnover of HK$54.70 million. The stock has been under sustained selling pressure as investors lock in gains following a series of major positive developments that had driven a sharp rally in prior sessions.

The company reported its interim results on August 27, posting first-half revenue of RMB 550 million, up 43.81% year-over-year, with net losses narrowing dramatically by 94.65% to just RMB 720,800. Earlier, the stock had surged over 50% in a single session on August 20 after Moderna's mRNA cancer vaccine achieved positive Phase III clinical trial results, a development seen as a platform-level re-rating catalyst given CANSINOBIO's similar development approach. On August 26, the stock rallied another 26% after the company announced a strategic cooperation agreement with deepGeneAI to co-develop personalized mRNA therapeutic cancer vaccines.

However, the stock price had already fully priced in these positive expectations ahead of the earnings release. Since August 27, shares have pulled back across multiple consecutive trading sessions as accumulated profit-taking pressure continues to be released, with today's decline extending the correction trend.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)